Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Ombudsman

- PMLiVE

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

- PMLiVE

EMA starts rapid review of Shire’s HAE antibody

The EU medicines regulator is expected to make a verdict in 150 days

- PMLiVE

AbbVie slumps on trial results for would-be blockbuster Rova-T

The pharma group saw its shares plummet after the news broke

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

Biogen Idec building

Biogen and AbbVie pull MS drug Zinbryta from the market

Potential risks of liver damage and immune-related conditions have been reported

- PMLiVE

AllTrials tracker site names clinical trial non-reporters

The FDAAA site seeks to highlight the failings of the FDA Amendments Act 2007

- PMLiVE

AbbVie reports more solid data for would-be psoriasis blockbuster

Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara

- PMLiVE

EMA’s Amsterdam home will not be ready in time

Staff will initially move to a temporary building in the city after Brexit

- PMLiVE

EMA hands UniQure orphan status first in Huntington’s

The Dutch biotech expects to file the treatment for approval later this year

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links